BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
BioCryst Pharmaceuticals missed estimated earnings by 33.33%, reporting an EPS of $-0.4 versus an estimate of $-0.3.
Revenue was up $43.14 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.04 which was followed by a 6.37% drop in the share price the next day.
Here's a look at BioCryst Pharmaceuticals's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.29 | -0.24 | -0.27 | -0.25 |
| EPS Actual | -0.33 | -0.24 | -0.36 | -0.34 |
| Revenue Estimate | 39.38M | 28.48M | 8.89M | 17.52M |
| Revenue Actual | 40.99M | 49.96M | 19.06M | 4.02M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
